2018
DOI: 10.1016/j.critrevonc.2018.03.009
|View full text |Cite
|
Sign up to set email alerts
|

Biological aspects of chondrosarcoma: Leaps and hurdles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
44
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 45 publications
(45 citation statements)
references
References 33 publications
1
44
0
Order By: Relevance
“…Chondrosarcoma is recognized as a malignant cartilage‐forming tumor, characterized by a relatively high mortality because of a considerable deficiency in response to current chemotherapy and radiotherapy . Emerging evidence indicates that tumor suppressor genes, oncogenes, and signaling transductions have already been demonstrated to contribute to chondrosarcoma development and progression . A full understanding of the key elements dictating the oncogenic phenotype and the molecular events underpinning the biology of chondrosarcoma undoubtedly helps discover novel target drugs to treat chondrosarcoma .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Chondrosarcoma is recognized as a malignant cartilage‐forming tumor, characterized by a relatively high mortality because of a considerable deficiency in response to current chemotherapy and radiotherapy . Emerging evidence indicates that tumor suppressor genes, oncogenes, and signaling transductions have already been demonstrated to contribute to chondrosarcoma development and progression . A full understanding of the key elements dictating the oncogenic phenotype and the molecular events underpinning the biology of chondrosarcoma undoubtedly helps discover novel target drugs to treat chondrosarcoma .…”
Section: Introductionmentioning
confidence: 99%
“…1 Emerging evidence indicates that tumor suppressor genes, oncogenes, and signaling transductions have already been demonstrated to contribute to chondrosarcoma development and progression. 2 A full understanding of the key elements dictating the oncogenic phenotype and the molecular events underpinning the biology of chondrosarcoma undoubtedly helps discover novel target drugs to treat chondrosarcoma. 3 Thus, it is an urgent need to develop novel molecular targeted therapies by exploring potential targets governing the pathogenesis of chondrosarcoma.…”
Section: Introductionmentioning
confidence: 99%
“…-Synthesis of fluorescent MCM-41 (1) FITC (5.5 mg) was dissolved in 3 mL of ethanol under argon, then APTES (12 µL) was added and the reaction was stirred for 2 hours at room temperature. In a separate flask, CTAB (0.5 g) was dissolved in a mixture of MilliQ water (240 mL) and NaOH 2M (1.75 mL), and the mixture was stirred at 80°C.…”
Section: Synthesis Of Mesoporous Silica Nanoparticlesmentioning
confidence: 99%
“…While there have been many attempts to improve survival and patient outcomes of this disease, large database studies have demonstrated that survival of chondrosarcoma has not changed in the past 30 years . Several molecular pathways have been identified as potential therapeutic targets, however the mainstay treatment of chondrosarcoma is surgical as this disease is generally considered to be radiation and chemotherapy‐resistant . Once chondrosarcoma metastasizes, it is considered essentially incurable because of a lack of effective systemic therapy.…”
mentioning
confidence: 99%